Funding for this research was provided by:
Innovation Fund Denmark (5164-00001B9)
Mental Health Services, Capital Region of Denmark, The Danish Council for Independent Research, Medical Sciences (DFF—4183-00570)
The Market Development Fund (2015-310)
The Innovation Fund, Denmark (5164-00001B)
Copenhagen Center for Health Technology (CACHET), EU H2020 ITN (EU project 722561)
Lundbeck Foundation (R215-2015-4121)
Received: 13 September 2021
Accepted: 27 October 2021
First Online: 1 December 2021
: The RADMIS trial: the RADMIS trial was approved by the Regional Ethics Committee in The Capital Region of Denmark and the data agency, Capital Region of Copenhagen (H-16046093, RHP-2017-005, I-Suite:05365) and registered at ClinicalTrials.gov (NCT03033420). The BIO study: the study protocol was approved by the Committee on Health Research Ethics of the Capital region of Denmark (protocol No. H-7-2014-007) and the Danish Data Protection Agency, Capital Region of Copenhagen (RHP-2015-023). Both studies complied with the Declaration of Helsinki (Seoul, October 2008). All participants provided written informed consent. Data from smartphones were stored by Monsenso subject to a data management agreement between Monsenso and The Capital Region of Denmark.
: All authors consent for publication of the present study.
: MFJ, DR, and JoB have no competing interests. MV has within the last 3 years been a consultant for Lundbeck, Sunovion and Janssen-Cilag. LVK has been a consultant for Lundbeck within the past 3 years. JB is a co-founder and shareholder in Monsenso.